Skip to main content
Top
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Case report

Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event

Authors: Christophe Maritaz, Carole Metz, Nabil Baba-Hamed, Méryam Jardin-Szucs, Gaël Deplanque

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Cetuximab is a commonly used antibody agent in the treatment of colorectal or head and neck cancer. Although it is generally well tolerated in most patients, cetuximab has been associated with some rare but serious adverse events. Aseptic meningitis is one such distinctly uncommon adverse drug reaction.

Case presentation

We present the case of a middle-aged Caucasian patient, who presented with fever and headache within a few hours of starting cetuximab therapy and was diagnosed with cetuximab-induced aseptic meningitis after a complete workup.

Conclusion

To our knowledge, this is the ninth case of cetuximab-induced aseptic meningitis reported in literature. Because of a nonspecific clinical presentation, this adverse drug reaction can be easily misdiagnosed. It is important to increase awareness of this potentially severe reaction among oncologists.
Literature
1.
go back to reference Moris G, Giarca-Mono JC. The challenge of drug-induce meningitis revisited. JAMA Intern Med. 2014;174:1511–2.CrossRefPubMed Moris G, Giarca-Mono JC. The challenge of drug-induce meningitis revisited. JAMA Intern Med. 2014;174:1511–2.CrossRefPubMed
2.
go back to reference Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259–62.CrossRefPubMed Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259–62.CrossRefPubMed
3.
go back to reference Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006;6:535–42.CrossRefPubMed Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006;6:535–42.CrossRefPubMed
4.
5.
go back to reference Mullane D, Williams L, Merwick A, et al. Drug induced aseptic meningitis caused by intravenous immunoglobulin therapy. Ir Med J. 2012;105:182–3.PubMed Mullane D, Williams L, Merwick A, et al. Drug induced aseptic meningitis caused by intravenous immunoglobulin therapy. Ir Med J. 2012;105:182–3.PubMed
6.
go back to reference Cherin P, Marie I, Michallet M, Pelus E, Dantal J, Crave JC, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15:71–81.CrossRefPubMed Cherin P, Marie I, Michallet M, Pelus E, Dantal J, Crave JC, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15:71–81.CrossRefPubMed
7.
go back to reference Wiles CM, Brown P, Chapel H, Guerrini R, Hughes RA, Martin TD, et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry. 2002;72:440–8.PubMedPubMedCentral Wiles CM, Brown P, Chapel H, Guerrini R, Hughes RA, Martin TD, et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry. 2002;72:440–8.PubMedPubMedCentral
8.
go back to reference Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Boss M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18:904–14.PubMed Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Boss M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18:904–14.PubMed
9.
go back to reference Emani MK, Zaiden Jr RA. Aseptic meningitis: a rare side effect of cetuximab therapy. J Oncol Pharm Pract. 2013;19:178–80.CrossRefPubMed Emani MK, Zaiden Jr RA. Aseptic meningitis: a rare side effect of cetuximab therapy. J Oncol Pharm Pract. 2013;19:178–80.CrossRefPubMed
10.
go back to reference Feinstein TM, Gibson MK, Argiris A. Cetuximab-induced aseptic meningitis. Ann Oncol. 2009;20:1609–10.CrossRefPubMed Feinstein TM, Gibson MK, Argiris A. Cetuximab-induced aseptic meningitis. Ann Oncol. 2009;20:1609–10.CrossRefPubMed
11.
go back to reference Ulrich A, Weiler S, Weller M, Rordorf T, Tarnutzer AA. Cetuximab induced aseptic meningitis. J Clin Neurosci. 2015;22:1061–3.CrossRefPubMed Ulrich A, Weiler S, Weller M, Rordorf T, Tarnutzer AA. Cetuximab induced aseptic meningitis. J Clin Neurosci. 2015;22:1061–3.CrossRefPubMed
12.
go back to reference Prasanna D, Elrafei T, Shum E, Strakhan M. More than a headache: a case of cetuximab-induced aseptic meningitis. BMJ Case Rep. 2015;12:2015. Prasanna D, Elrafei T, Shum E, Strakhan M. More than a headache: a case of cetuximab-induced aseptic meningitis. BMJ Case Rep. 2015;12:2015.
13.
go back to reference Nagovskiy N, Agarwal M, Allerton J. Cetuximab-induced aseptic meningitis. J Thorac Oncol. 2010;5:751.CrossRefPubMed Nagovskiy N, Agarwal M, Allerton J. Cetuximab-induced aseptic meningitis. J Thorac Oncol. 2010;5:751.CrossRefPubMed
Metadata
Title
Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event
Authors
Christophe Maritaz
Carole Metz
Nabil Baba-Hamed
Méryam Jardin-Szucs
Gaël Deplanque
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2434-7

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine